AGEN vs BMY
AGEN: A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term revenue through royalty sales and partnerships. BMY: Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse modalities like biologics and CAR-T cell technology.
Side-by-side fundamentals
| Metric | AGEN | BMY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.53 | $60.76 | |
| Market cap as of 2026-07-23 | $232M | $124.9B | |
| P/E as of 2026-07-23 | 3.60 | 20.91 | AGEN lower |
| PEG as of 2026-07-23 | n/a | -4.29 | |
| Net margin as of 2026-07-23 | +52.2% | +12.3% | AGEN higher |
| Gross margin as of 2026-07-23 | +99.3% | +53.7% | AGEN higher |
| Operating margin as of 2026-07-23 | +87.9% | +17.1% | AGEN higher |
| ROE as of 2026-07-23 | +76.6% | +41.6% | AGEN higher |
| ROA as of 2026-07-23 | +31.1% | +8.7% | AGEN higher |
| Debt / equity as of 2026-07-23 | 4.01 | 2.22 | BMY lower |
| Revenue growth (YoY) as of 2026-07-23 | +24.5% | +1.8% | AGEN higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +1.4% | AGEN higher |
| Dividend yield as of 2026-07-23 | n/a | +4.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.48 | 0.23 | |
| 1-year return as of 2026-07-22 close | -8.4% | +26.5% | BMY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.